patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
drug · antibody
glofitamab
Marketedupdated 2mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Approvedcommunity read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and diffuse large b-cell lymphoma and 6 investigational indications.
indications
investigational
DLBCL
targets
B-lymphocyte antigen CD20T cell surface glycoprotein CD3
all catalysts(3)
approval · 3
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that